A7584658
Epalrestat , 2mMinDMSO , 82159-09-9
Synonym(s):
(5Z)-5-[(2E)-2-Methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid
CAS NO.:82159-09-9
Empirical Formula: C15H13NO3S2
Molecular Weight: 319.4
MDL number: MFCD00865484
EINECS: 675-018-0
Pack Size | Price | Stock | Quantity |
1ml | RMB159.20 | In Stock |
|
others | Enquire |
Update time: 2022-07-08
PRODUCT Properties
Melting point: | 210-217 C |
Boiling point: | 516.8±60.0 °C(Predicted) |
Density | 1.43±0.1 g/cm3(Predicted) |
storage temp. | -20°C |
solubility | DMSO: soluble5mg/mL, clear (warmed) |
pka | 3.62±0.10(Predicted) |
form | powder |
color | yellow to orange |
Merck | 14,3605 |
Stability: | Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20° for up to 2 months. |
InChI | InChI=1S/C15H13NO3S2/c1-10(7-11-5-3-2-4-6-11)8-12-14(19)16(9-13(17)18)15(20)21-12/h2-8H,9H2,1H3,(H,17,18)/b10-7+,12-8- |
InChIKey | CHNUOJQWGUIOLD-NFZZJPOKSA-N |
SMILES | S1/C(=C\C(\C)=C\C2=CC=CC=C2)/C(=O)N(CC(O)=O)C1=S |
Description and Uses
Epalrestat is the second aldose reductase inhibitor to be introduced worldwide and the first to be launched in Japan. The compound is indicated for the treatment of diabetic neuropathy. It is also being investigated for diabetic retinopathy and nephropathy.
An aldose reductase inhibitor. It is used in treatment of diabetic neuropathy.
Safety
Symbol(GHS) | GHS06 |
Signal word | Danger |
Hazard statements | H300 |
Precautionary statements | P264-P270-P301+P310+P330-P405-P501 |
RIDADR | 2811 |
WGK Germany | 3 |
RTECS | XJ5131855 |
HS Code | 2932.99.7000 |
HazardClass | 6.1 |
PackingGroup | II |